ATE145214T1 - Sulphonamid-derivate - Google Patents

Sulphonamid-derivate

Info

Publication number: ATE145214T1
Authority: AT; Austria
Prior art keywords: cathepsin; sulphonamide derivatives; amyotrophia; calpain; hypercalcemia
Prior art date: 1993-04-28

Application number

AT94106225T

Other languages

English (en)

Inventor

Ryoichi Ando

Toshiro Sakaki

Chizuko Takahashi

Yoshiyuki Fujimura

Original Assignee

Mitsubishi Chem Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-28

Filing date

1994-04-21

Publication date

1996-11-15

1994-04-21 Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp

1996-11-15 Application granted granted Critical

1996-11-15 Publication of ATE145214T1 publication Critical patent/ATE145214T1/de

Links

150000003456 sulfonamides Chemical class 0.000 title abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
108010032088 Calpain Proteins 0.000 abstract 1
102000007590 Calpain Human genes 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
108090000712 Cathepsin B Proteins 0.000 abstract 1
102000004225 Cathepsin B Human genes 0.000 abstract 1
108090000619 Cathepsin H Proteins 0.000 abstract 1
102000004175 Cathepsin H Human genes 0.000 abstract 1
108090000624 Cathepsin L Proteins 0.000 abstract 1
102000004172 Cathepsin L Human genes 0.000 abstract 1
108010005843 Cysteine Proteases Proteins 0.000 abstract 1
102000005927 Cysteine Proteases Human genes 0.000 abstract 1
208000037147 Hypercalcaemia Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
108090000526 Papain Proteins 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
230000000148 hypercalcaemia Effects 0.000 abstract 1
208000030915 hypercalcemia disease Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
201000000585 muscular atrophy Diseases 0.000 abstract 1
201000006938 muscular dystrophy Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
235000019834 papain Nutrition 0.000 abstract 1
229940055729 papain Drugs 0.000 abstract 1
229940124530 sulfonamide Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

AT94106225T 1993-04-28 1994-04-21 Sulphonamid-derivate ATE145214T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP10278293		1993-04-28

Publications (1)

Publication Number	Publication Date
ATE145214T1 true ATE145214T1 (de)	1996-11-15

Family

ID=14336717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94106225T ATE145214T1 (de)	1993-04-28	1994-04-21	Sulphonamid-derivate

Country Status (10)

Country	Link
US (1)	US5506243A (de)
EP (1)	EP0623627B1 (de)
JP (1)	JP3599287B2 (de)
AT (1)	ATE145214T1 (de)
CA (1)	CA2121523C (de)
DE (1)	DE69400887T2 (de)
DK (1)	DK0623627T3 (de)
ES (1)	ES2096370T3 (de)
GR (1)	GR3022524T3 (de)
TW (1)	TW261608B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863902A (en) *	1995-01-06	1999-01-26	Sibia Neurosciences, Inc.	Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) *	1995-01-06	1998-09-08	Sibia Neurosciences, Inc.	Peptide and peptide analog protease inhibitors
EP0928786B1 (de) *	1995-10-25	2003-01-02	Senju Pharmaceutical Co., Ltd.	Angiogenese Inhibitoren
US6214800B1 (en)	1995-10-25	2001-04-10	Senju Pharmaceutical Co., Ltd.	Angiogenesis inhibitor
DE69625622T2 (de) *	1995-10-25	2003-08-14	Senju Pharmaceutical Co., Ltd.	Angiogenese Inhibitoren
ATE377006T1 (de) *	1995-11-28	2007-11-15	Cephalon Inc	Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
US6653331B2 (en) *	1996-07-03	2003-11-25	Pharmacia & Upjohn Company	Targeted drug delivery using sulfonamide derivatives
AU3805497A (en) *	1996-07-19	1998-02-10	Neurotrauma Therapeutics, Inc.	Calpain inhibitors for the treatment of traumatic brain injury
AU4042397A (en) *	1996-07-19	1998-02-10	Neurotrauma Therapeutics, Inc.	Calpain inhibitors for the treatment of cerebral ischemia, spinal cord injury or stroke
AU4489397A (en)	1996-10-31	1998-05-22	Alcon Laboratories, Inc.	The use of calpain inhibitors to treat ocular neural pathology
US5874449A (en) *	1996-12-31	1999-02-23	Gpi Nil Holdings, Inc.	N-linked sulfonamides of heterocyclic thioesters
NZ335480A (en)	1996-12-31	2001-04-27	Guilford Pharm Inc	Neurotrophic low molecular weight N-linked sulfonamides of heterocyclic thioesters and their use as inhibitors of immunophilin proteins
AR013079A1 (es) *	1997-05-06	2000-12-13	Smithkline Beecham Corp	Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
AU2745599A (en)	1998-03-05	1999-09-20	Senju Pharmaceutical Co., Ltd.	Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
US6331537B1 (en)	1998-06-03	2001-12-18	Gpi Nil Holdings, Inc.	Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
IL140040A0 (en)	1998-06-03	2002-02-10	Guilford Pharm Inc	N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
WO2000021550A2 (en) *	1998-10-13	2000-04-20	President And Fellows Of Harvard College	Methods and compositions for treating neurodegenerative diseases
US7253169B2 (en)	1999-11-12	2007-08-07	Gliamed, Inc.	Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en)	1999-11-12	2002-07-09	Gpi Nil Holdings, Inc.	AZA compounds, pharmaceutical compositions and methods of use
EP1244670B1 (de)	1999-12-21	2006-03-08	MGI GP, Inc.	Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
AU2001228811A1 (en) *	2000-01-26	2001-08-07	Ono Pharmaceutical Co. Ltd.	Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
WO2002010768A2 (en) *	2000-07-31	2002-02-07	The Regents Of The University Of California	Model for alzheimer's disease and other neurodegenerative diseases
JPWO2002034252A1 (ja) *	2000-10-26	2004-03-04	千寿製薬株式会社	ジペプチジルアルデヒド誘導体含有医薬組成物
JP2004517892A (ja)	2000-12-13	2004-06-17	ワイス	β−アミロイド産生の複素環スルホンアミド阻害剤
AU2003248059A1 (en) *	2002-07-22	2004-02-09	Senju Pharmaceutical Co., Ltd.	NOVEL Alpha-KETOAMIDE DERIVATIVE AND USE THEREOF
EP1761485A1 (de)	2003-06-04	2007-03-14	Schering AG	Amidinoverbindungen als cysteinproteaseinhibitoren
PT1663958E (pt)	2003-09-18	2015-06-01	Virobay Inc	Compostos contendo haloalquilo como inibidores de protease de cisteína
EP1819667B1 (de)	2004-12-02	2012-10-17	ViroBay, Inc.	Sulfonamidverbindungen als cysteinprotease-inhibitoren
US7488848B2 (en)	2005-03-21	2009-02-10	Virobay, Inc.	Alpha ketoamide compounds as cysteine protease inhibitors
US7893093B2 (en)	2005-03-22	2011-02-22	Virobay, Inc.	Sulfonyl containing compounds as cysteine protease inhibitors
WO2008045017A2 (en) *	2005-06-22	2008-04-17	Diamond Scott L	Sars and ebola inhibitors and use thereof, and methods for their discovery
US7893112B2 (en)	2006-10-04	2011-02-22	Virobay, Inc.	Di-fluoro containing compounds as cysteine protease inhibitors
EP2079683B1 (de)	2006-10-04	2015-01-21	Virobay, Inc.	Difluorhaltige verbindungen als cysteinproteasehemmer
US8324417B2 (en)	2009-08-19	2012-12-04	Virobay, Inc.	Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
JP2021514010A (ja) *	2018-02-20	2021-06-03	エッジワイズセラピューティクス，インコーポレイテッド	運動障害を処置するための方法および組成物
JP7355777B2 (ja)	2021-03-31	2023-10-03	本田技研工業株式会社	切削工具
WO2024018245A1 (en)	2022-07-22	2024-01-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en)	2023-01-20	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Autophagy activators for the treatment of rhabdomyolysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5754157A (en) *	1980-09-19	1982-03-31	Nippon Kayaku Co Ltd	L-argininal derivative and its preparation
JP2701932B2 (ja) *	1989-04-10	1998-01-21	サントリー株式会社	タンパク質分解酵素阻害剤
EP0504938A3 (en) *	1991-03-22	1993-04-14	Suntory Limited	Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient

1994
- 1994-04-05 JP JP6724294A patent/JP3599287B2/ja not_active Expired - Fee Related
- 1994-04-08 TW TW083103077A patent/TW261608B/zh active
- 1994-04-18 CA CA002121523A patent/CA2121523C/en not_active Expired - Fee Related
- 1994-04-21 AT AT94106225T patent/ATE145214T1/de not_active IP Right Cessation
- 1994-04-21 EP EP94106225A patent/EP0623627B1/de not_active Expired - Lifetime
- 1994-04-21 DK DK94106225.9T patent/DK0623627T3/da active
- 1994-04-21 DE DE69400887T patent/DE69400887T2/de not_active Expired - Fee Related
- 1994-04-21 ES ES94106225T patent/ES2096370T3/es not_active Expired - Lifetime
- 1994-04-28 US US08/233,963 patent/US5506243A/en not_active Expired - Fee Related
1997
- 1997-02-12 GR GR970400212T patent/GR3022524T3/el unknown

Also Published As

Publication number	Publication date
DE69400887D1 (de)	1996-12-19
ES2096370T3 (es)	1997-03-01
CA2121523C (en)	2006-06-20
DE69400887T2 (de)	1997-05-22
US5506243A (en)	1996-04-09
JPH0748340A (ja)	1995-02-21
GR3022524T3 (en)	1997-05-31
CA2121523A1 (en)	1994-10-29
JP3599287B2 (ja)	2004-12-08
EP0623627B1 (de)	1996-11-13
DK0623627T3 (da)	1997-04-28
TW261608B (de)	1995-11-01
EP0623627A1 (de)	1994-11-09

Legal Events

Date	Code	Title	Description
1997-06-15	UEP	Publication of translation of european patent specification
2001-01-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69400887D1 (de)	1996-12-19	Sulphonamid-Derivate
CA2217737A1 (en)	1996-10-24	Thf-containing sulfonamide inhibitors of aspartyl protease
DE69317992D1 (de)	1998-05-20	Aminoketonderivate
EP0885887A3 (de)	1999-02-03	Sulfonamide Inhibitore von HIV-Aspartyl Protease
AP9600827A0 (en)	1997-10-17	Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease.
EP0739338A4 (de)	1997-03-26	Neue sterin-protease inhibitoren: isothiazolidin-3-on-1,1-dioxid und 3-oxo-1,2,5-thiadiazolidin 1,1-dioxid
AP1717A (en)	2007-01-30	Sulfonamide inhibitors of aspartyl protease.
DE60214392D1 (de)	2006-10-12	1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
ES2091068T3 (es)	1996-10-16	Combinaciones de productos activos fungicidas.
PT1052250E (pt)	2004-11-30	Inibidores de protease retroviral sulfonilalcanoilamino hidroxietilamino sulfonamidas
DE69624346D1 (de)	2002-11-21	Verbindung der struktur aminosäure-hydroxyethylamino-sulfonamide als inhibitoren der retroviralen protease
FI950650A0 (fi)	1995-02-14	Retrovirusproteaasi-inhibiittoreina käyttökelpoisia hydroksietyyliaminosulfoniamideja
NO20033918L (no)	2003-09-04	Ny anvendelse av peptidklasse av forbindelser for behandling av allodyni eller andre typer av kronisk smerte eller fantomsmerte
DE60039244D1 (de)	2008-07-31	HEXAHYDROFUROi2,3-B FURAN-3-YL-N- 3-i(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMAT ALS RETROVIRUSPROTEASEHEMMER
CA2150131A1 (en)	1994-06-23	Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity
DZ3008A1 (fr)	2004-03-27	Inhibiteurs de l'aspartyle protéase.
EP1637139A3 (de)	2006-08-16	Neue Verwendung von HIV-Protease Hemmern
NO974322L (no)	1997-11-24	DNA som koder for human papillomvirus type 18
ES2177024T3 (es)	2002-12-01	Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
NO942983L (no)	1995-02-14	Farmasöytiske sammensetninger
ATE250021T1 (de)	2003-10-15	Hydroxycyclopentanone
DE59409628D1 (de)	2001-02-08	Lagerstabile wässrige Lösungen von Isothiazolin-3-onen
WO2002057246A3 (en)	2002-11-21	Inhibitors of cruzipain and other cysteine proteases
ATE277924T1 (de)	2004-10-15	Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
WO2002057248A3 (en)	2002-10-03	Inhibitors of cruzipain and other cysteine proteases